70. 広範脊柱管狭窄症 Spinal stenosis Clinical trials / Disease details
臨床試験数 : 96 / 薬物数 : 203 - (DrugBank : 60) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 89
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2011-006152-36-DK (EUCTR) | 10/05/2012 | 10/05/2012 | Does postoperative treatment with parathyroidea hormone Forteo®improve the disability inelderly patients undergoing spinal stabilization fusion surgery comparedwith patients treated with placebo. If that is the case, is there a correlationbetween improvement of disability and solid osseous healing? | Postoperative treatment with parathyroidea hormone Forteo® inpatients undergoing posterolateral spinal fusion surgery. A prospektiveand a randomized double-blinded, placebo-controlled study - PTH-U-DESE-STUDY | Spinal stenosis MedDRA version: 14.1;Level: LLT;Classification code 10041597;Term: Spinal stenosis of lumbar region;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Trade Name: Forteo Product Name: Forsteo Product Code: 0002-8971 INN or Proposed INN: teriparatide [rDNA origin] contains recombinant human parathyroid hormone (1-34) Other descriptive name: rhPTH (1-34) | Middelfart Rygsektor | NULL | Not Recruiting | Female: yes Male: yes | 100 | Phase 2 | Denmark |